Upstate Active Clinical Trials
Study Title:Autologous Hematopoietic Stem Cell Transplantation After Melphalan with or without Total Body Irradiation for Multiple Myeloma.
What is the purpose of the study?To provide autologous transplantation for patients with mulitiple myeloma.
Upstate Institutional Review Board (IRB) Number:275099
Study/Protocol ID:BMT 9301
Patient Age Group:Adults
Principal Investigator:Dorothy C Pan, MD
Who is eligible?Diagnosis of multiple myeloma, acceptable laboratory values, HIV negative, no serious or uncontrolled organ dysfunction.
What is involved if I participate?
- How long is the study?
Inpatient stay approximately 21days, followed for lifetime
- Is transportation provided or reimbursed?
- Is parking provided or reimbursed?
- What tests and procedures are involved?
Detailed history & physical to determine eligibility, laboratory tests, x-rays/scans, as necessary, bone marrow biopsy & aspirate as necessary, laboratory tests during hospital admission, dental clearance prior to transplant.
Where will the study take place?SUNY Upstate Medical University,Syracuse, NY
Who can I contact for more information?
Name: Shramika Pokharel, MBBS, MPH